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Abstract
Background: Neurofibromatosis type 1 (NF1) is a
cancer syndrome associated with many different
cancer types. There are limited studies examining
melanoma risk in this population.
Objective: To identify melanoma cases in NF1
patients and compare melanoma incidence rates
relative to a general population sample.
Methods: A retrospective single institution case
review of 857 NF1 patients (seen from 7/1997 to
7/2017) was conducted. We calculated age- and
calendar period-adjusted standardized incidence
ratios (SIRs) for white patients >20 years old
overall (N=282) and for females (N=156) at their
last visit date. We obtained general population
melanoma reference rates from the Surveillance,
Epidemiology, and End Results (SEER) 9 database.
Results: Among 857 patients, 52.2% were female,
54% were <20 (mean±sd=10.9±4.6) years old, and
46% were >20 (40.4±14.9) years old at their last
visit date. One white female patient had a
malignant melanoma diagnosed at 47 years old.
The adjusted SIR was 0.97 (95% CI 0.05-4.78)
overall (N=282) and 1.62 (95% CI 0.08-7.98) for
females (N=156).
Conclusions: We did not find statistical evidence
for an increased melanoma risk in adults with NF1.
However, additional large studies are warranted to
clarify whether melanoma risk is increased in NF1
patients.

Keywords: malignant melanoma, neurofibromatosis
type 1

Introduction
Neurofibromatosis type 1 (NF1) is an autosomal
dominant disorder with a prevalence of
approximately 1 in 3,000 [1]. Neurofibromatosis
type 1 results from germline mutations in the NF1
gene encoding the neurofibromin protein.
Neurofibromin is a negative regulator of neural
crest-derived tissue growth and differentiation. In
this regard, NF1 mutations have been associated
with an increased risk of neural crest tumors,
including malignant peripheral neural sheath
tumors (MPNSTs), peripheral nerve sheath tumors
(neurofibromas),
and
pheochromocytomas.
Although melanocytes are also of neural crest
origin and the NF1 gene is a frequently mutated
gene in sporadic melanoma [2-3], there is a lack
of convincing evidence for an increased risk of
malignant melanoma in patients with NF1. Prior
case reports have suggested a relationship
between melanoma and NF1, but larger
population-based studies have not provided clear
evidence for an association [4-13]. Given the small
number of studies focused on this cancer type in
NF1, we sought to evaluate the risk of melanoma
in people with NF1.
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Methods
A retrospective case review was conducted to
identify individuals with NF1 and melanoma
following approval by the Washington University
Institutional Review Board spanning visits
between July 1997 and July 2017. We used a
previously compiled neurofibromatosis patient
medical record registry [14-15] as the initial
patient cohort and added additional patients seen
during the expanded study period. We used a
REDCap
database
(https://projectredcap.org/software/) to capture
all study data. Patient records, including physician
notes
(history
and
physical),
patient
questionnaires, anesthesia records, outpatient
surgery and pre-hospitalization forms, imaging
records, administrative notes, and inpatient
records, were examined for a documented NF1
diagnosis; patients without a documented NF1
diagnosis were excluded from analysis (N=130).
Patient records were also examined for age, sex,
race/ethnicity, and reported melanoma or
melanoma in situ diagnoses along with the age at
diagnosis. For patients with a diagnosis of
melanoma, Breslow depth, stage of disease,
histological subtype, and clinical course were
noted.

2002, 2003-2007, 2008-2012, and 2013-2014)
from the Surveillance, Epidemiology, and End
Results (SEER) 9 [16] database using SEER*Stat
software [17] with selection criteria of white race
using the “Race recode (White, Black, Other)”
variable and “Melanoma of the Skin” using the
“Site recode ICD-O-3/WHO 2008” variable [16].
We calculated age group and calendar period
specific person-years at risk for each subject as
the person-time contributed to a specific age
group calendar period interval starting at age 20
years old using Statistical Analysis Software
(Version 9.4, Cary, NC). Person-time was censored
in a specific age group calendar period interval if
the date of melanoma diagnosis, death, or last
follow-up as defined by the visit date of the last
record occurred during that interval. The total
person-years at risk for each sex in each age
group and calendar year interval was multiplied
by the corresponding age group and calendar
period sex-specific incidence rate from SEER to
generate the expected number of cases for that
interval. This number was then summed across
each age group and calendar year interval to yield
the total expected number of melanoma cases in
our NF1 cohort for each sex. Finally, the expected

To compare risk of melanoma in our NF1 cohort
to the general population, age and calendar year
standardized incidence ratios (SIRs) were
calculated. For this calculation, we only included
individuals with a reported race of white and who
were >20 years old at their last visit (N=282), since
melanoma is extremely rare in individuals <20
years of age and in those who are non-white. In
addition, we did not observe any melanoma cases
in these groups. General population melanoma
age-adjusted incidence rates were obtained by
sex, age group (20-24, 25-29, 30-34, 35-39, 40-44,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, and >80
years), and calendar period (1973-1977, 19781982, 1983-1987, 1988-1992, 1993-1997, 1998-2-

Table 1. Baseline characteristics of study patients.
Variable
Age category
< 18 years
≥ 18 years
Sex
Male
Female
Race/Ethnicity
White
Black
Hispanic
Asian
Other/Unknown
Melanoma diagnoses
<18 years
≥18 years

N (%)
432 (50.4)
425 (49.6)
410 (47.8)
447 (52.2)
632 (73.8)
184 (21.5)
11 (1.3)
10 (1.2)
20 (2.2)
0 (0)
1 (0.1)
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number for both sexes summed and for females
was divided by the observed number of cases,
respectively, to calculate SIRs. Fisher’s exact test P
values and 95% CIs for the SIRs were calculated
using
OpenEpi
software
(http://www.openepi.com/SMR/SMR.htm). A post
hoc power calculation was performed in R
software version 3.5.0 using the function
power.smr.test
referenced
at
https://rdrr.io/github/clayford/bme/man/power.s
mr.test.html.

Results
A total of 857 patients had a medical recordverified diagnosis of NF1. There were more
females than males in the cohort with 447 female
(52.2%) and 410 male (47.8%) patients. Four
hundred sixty-two (53.9%) patients were <20
years, whereas the remainder were >20 years old
on the last visit date during the study period. The

mean age for those <20 years was 10.9±4.6 years
(range 0-19 years) whereas for those >20 years
was 40.4±14.9 years (range 20-86 years). The
distribution of reported race/ethnicity was 73.6%
white (N=632), 21.5% black (N=184), 1.3%
hispanic (N=11), 1.2% asian (N=10), and 2.3%
other or unknown (N=20). A total of 282 patients
with NF1 and reported white race who were >20
years old (mean±sd=39.4±14.3, range 20-81
years) on their last visit date were included in the
SIR calculation. They had a similar sex distribution
as the overall group with 156 (55.3%) female and
126 (44.7%) male patients (Table 1).
We identified one individual with a malignant
melanoma diagnosis in their record among the
857 patients. The patient was a 47-year-old white
woman with a history of NF1 diagnosed in
childhood, complicated by pheochromocytoma
status post right adrenalectomy and a right above
the knee amputation due to NF1-associated

Table 2. Literature review of the association between NF1 and melanoma from studies that calculated prevalence and risk
estimates.
Authors
Brasfield & Das
Gupta [4]
Guillot et al. [5]
Hope et al. [6]
Knight et al. [7]
Rasmussen et al. [8]
Rubenstein et al. [9]
Seminog et al. [10]
Sorensen et al. [11]
Uusitalo et al. [12]
Zoller et al. [13]

Publication findings
Six melanomas in 110 patients, 3 from giant congenital
nevi
Eleven patients with melanoma: 3 melanomas in 671
patients at 4 centers with NF1 and melanoma registries
and 8 melanomas in an unknown number of patients at
an additional 6 centers
No melanomas identified in 395 patients
One melanoma in 45 patients
Melanoma listed as cause of death in 12 of 3770 NF1
patients compared to cause of death on death
certificates in the general population
Four melanomas in 791 patients
Nineteen melanomas in 6739 NF1 patients compared to
rates of melanoma in a linked data set of hospital
admissions in England
One melanoma in 212 patients
Three melanomas in 1404 NF1 patients compared to
rates of melanoma in an age, calendar and gender
adjusted Finish cohort
One melanoma in 70 patients

Prevalence

Risk estimate

5.5%

0.45%
0%
2.2%
0.32%

PMR 0.52
(95% CI 0.27-0.90)

0.51%
0.28%

RR 3.60
(95% CI 2.20–5.60)

0.47%
0.21%

SIR 1.58
(95% CI 0.32-4.60)

1.4%

PMR = proportional mortality ratio, CI = confidence interval, RR = relative risk, SIR = standardized incidence ratio.
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skeletal deformities. She had no history of
dysplastic nevi. She initially presented with
abdominal pain and vomiting in the emergency
room and a CT abdomen and pelvis showed
extensive tumors throughout her body including
in her lungs, liver, kidneys, and lymph nodes. A
biopsy of a right inguinal lymph node was
diagnostic for metastatic melanoma with
unknown primary, and immunohistochemistry
was negative for the BRAFV600 mutation. She was
started on ipilimumab and got four rounds of
therapy before dying from respiratory failure two
months after her initial diagnosis.
The age, sex, and calendar year adjusted SIR
among the 282 subjects included in the SIR
calculation was 0.97 (95% CI 0.05-4.78, P=0.55).
For females, the SIR was 1.62 (95% CI 0.08-7.98,
P=0.92).

Discussion
The findings described in our study add to
previous reports, with no statistically significant
evidence for an increased risk of melanoma in the
NF1 population. Although there have been many
case reports and small case series postulating a
link between NF1 and melanoma, larger studies
have not consistently revealed statistically
significant evidence for an increased melanoma
risk in adults with NF1. Seminog et al. [10] found
an increased melanoma risk in NF1 patients, with
19 melanoma cases in 6,739 NF1 patients
(prevalence 0.28%) and an age, sex, and calendar
year adjusted increased relative risk of 3.6 (95% CI
2.2-5.6) versus the general population. However,
a large Finnish study by Uusitalo et al. [12] did not
find statistical evidence for an increased incidence
of melanoma, identifying three patients with
melanoma out of 1,404 NF1 patients (prevalence
0.21%), with an age, sex, and calendar-year
adjusted SIR of 1.58 (95% CI 0.32-4.60, P=0.67).

Other studies noted a prevalence of melanoma in
smaller NF1 cohorts ranging from 0-5.5% [4-13].
An increased melanoma risk in NF1 patients is
plausible given that NF1 mutations are found in a
subset of sporadic melanomas, especially those
associated with chronically sun-damaged skin,
older age, desmoplastic type, and higher
mutational burden [18-22]. Additionally, NF1 loss
in melanoma has been associated with other
mutations in the RAS pathway, including RAS p21
protein activator 2 (RASA2), PTPN11, SOS1, RAF1,
and SPRED1 [17]. This finding suggests that
multiple mutations in the RAS pathway may be
necessary to progress to malignant melanoma
and that the NF1 mutation alone is not sufficient
by itself to cause melanoma.
A possible reason for a lack of strong evidence for
an increased melanoma risk in NF1 may reflect
decreased sun exposure in this patient
population. Although patients with NF1 are not
usually counseled to avoid sunlight, they may do
so because of physical and mental disabilities as
well as social isolation. Johnson et al. [23] found
that children with NF1 without orthopedic
impairments had decreased participation in a
variety of physical and social activities. Feelings of
loneliness [24] and social self-consciousness [25]
have also been reported in older individuals with
NF1. It is possible that the social isolation
experienced by many people with NF1 may result
in decreased sun exposure, offsetting any
increased risk for melanoma that would be
expected to occur as a result of a germline NF1
mutation. Further research is needed to test this
hypothesis.
The current study has some limitations. First, there
was a large proportion of pediatric patients in the
cohort, whereas melanoma predominantly affects
older individuals. However, given that increased
malignancy risk of NF1 is higher at younger ages,

-4-

Volume 25 Number 11| November 2019|
25(11):2

Dermatology Online Journal || Original Article

this study is still relevant in showing no cases of
melanoma in a pediatric population. Second,
although this is one of the larger studies on this
topic, it represents a single institution study that
is underpowered. Given our relatively small
sample size and confidence intervals for SIRs
overall and for females that are compatible with
larger risks, we cannot exclude the possibility of
an increased risk for melanoma in the NF1
population. A post hoc power calculation
indicated 80% power to detect an SIR of 8, which
would mark a strongly increased risk of
melanoma. Third, owing to the retrospective
nature of the study, the dataset may be
incomplete if patients were seen outside our
institution. However, as a tertiary care center with

a large oncology outpatient center, it can be
presumed that patients diagnosed with invasive
melanoma at outside institutions would be
referred back to our institution in some capacity
for surgery, oncology, or long-term follow up in a
high-risk skin cancer patient.

Conclusion
The findings reported herein contribute to the
existing literature on melanoma risk in NF1
patients, which is important when counseling
patients with this disorder.
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